Qingdao Baheal Medical INC. (301015) - Net Assets
Based on the latest financial reports, Qingdao Baheal Medical INC. (301015) has net assets worth CN¥2.90 Billion CNY (≈ $424.16 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥8.57 Billion ≈ $1.25 Billion USD) and total liabilities (CN¥5.67 Billion ≈ $829.59 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See 301015 equity to assets ratio to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.90 Billion |
| % of Total Assets | 33.83% |
| Annual Growth Rate | 14.16% |
| 5-Year Change | 26.11% |
| 10-Year Change | N/A |
| Growth Volatility | 19.26 |
Qingdao Baheal Medical INC. - Net Assets Trend (2018–2025)
This chart illustrates how Qingdao Baheal Medical INC.'s net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see 301015 market cap overview.
Annual Net Assets for Qingdao Baheal Medical INC. (2018–2025)
The table below shows the annual net assets of Qingdao Baheal Medical INC. from 2018 to 2025. Also explore net asset momentum of Qingdao Baheal Medical INC. to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.74 Billion ≈ $401.22 Million |
+5.27% |
| 2024-12-31 | CN¥2.60 Billion ≈ $381.15 Million |
-16.50% |
| 2023-12-31 | CN¥3.12 Billion ≈ $456.47 Million |
+36.86% |
| 2022-12-31 | CN¥2.28 Billion ≈ $333.53 Million |
+4.84% |
| 2021-12-31 | CN¥2.17 Billion ≈ $318.14 Million |
+45.06% |
| 2020-12-31 | CN¥1.50 Billion ≈ $219.31 Million |
+14.80% |
| 2019-12-31 | CN¥1.31 Billion ≈ $191.03 Million |
+20.32% |
| 2018-12-31 | CN¥1.08 Billion ≈ $158.76 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Qingdao Baheal Medical INC.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 362.7% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.59 Billion | 64.51% |
| Other Components | CN¥874.29 Million | 35.49% |
| Total Equity | CN¥2.46 Billion | 100.00% |
Qingdao Baheal Medical INC. Competitors by Market Cap
The table below lists competitors of Qingdao Baheal Medical INC. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Nyocor Co Ltd
SHG:600821
|
$1.81 Billion |
|
Sharplink Gaming Ltd
NASDAQ:SBET
|
$1.81 Billion |
|
CBIZ Inc
NYSE:CBZ
|
$1.81 Billion |
|
Live Oak Bancshares, Inc.
NYSE:LOB
|
$1.81 Billion |
|
Zhejiang HangKe Technology Co Ltd
SHG:688006
|
$1.81 Billion |
|
Zhong Yang Financial Group Limited Ordinary Shares
NASDAQ:TOP
|
$1.81 Billion |
|
Transwarp Technology (Shanghai) Co. Ltd. A
SHG:688031
|
$1.81 Billion |
|
Kuaijishan Shaoxing Rice Wine
SHG:601579
|
$1.81 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Qingdao Baheal Medical INC.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,374,910,404 to 2,463,146,955, a change of 88,236,551 (3.7%).
- Net income of 474,685,026 contributed positively to equity growth.
- Dividend payments of 467,570,633 reduced retained earnings.
- Other comprehensive income decreased equity by 300,833,478.
- Other factors increased equity by 381,955,636.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥474.69 Million | +19.27% |
| Dividends Paid | CN¥467.57 Million | -18.98% |
| Other Comprehensive Income | CN¥-300.83 Million | -12.21% |
| Other Changes | CN¥381.96 Million | +15.51% |
| Total Change | CN¥- | 3.72% |
Book Value vs Market Value Analysis
This analysis compares Qingdao Baheal Medical INC.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.02x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 10.33x to 5.02x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | CN¥2.28 | CN¥23.51 | x |
| 2019-12-31 | CN¥2.71 | CN¥23.51 | x |
| 2020-12-31 | CN¥3.13 | CN¥23.51 | x |
| 2021-12-31 | CN¥4.35 | CN¥23.51 | x |
| 2022-12-31 | CN¥4.40 | CN¥23.51 | x |
| 2023-12-31 | CN¥5.40 | CN¥23.51 | x |
| 2024-12-31 | CN¥4.40 | CN¥23.51 | x |
| 2025-12-31 | CN¥4.69 | CN¥23.51 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Qingdao Baheal Medical INC. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 19.27%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.32%
- • Asset Turnover: 0.93x
- • Equity Multiplier: 3.29x
- Recent ROE (19.27%) is below the historical average (21.66%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 24.01% | 7.07% | 1.39x | 2.44x | CN¥150.60 Million |
| 2019 | 16.39% | 4.33% | 1.41x | 2.68x | CN¥81.80 Million |
| 2020 | 18.53% | 4.64% | 1.45x | 2.75x | CN¥125.52 Million |
| 2021 | 19.54% | 5.98% | 1.53x | 2.13x | CN¥205.91 Million |
| 2022 | 21.81% | 6.69% | 1.47x | 2.22x | CN¥271.92 Million |
| 2023 | 24.63% | 8.62% | 1.29x | 2.22x | CN¥422.96 Million |
| 2024 | 29.12% | 8.54% | 1.14x | 2.99x | CN¥454.10 Million |
| 2025 | 19.27% | 6.32% | 0.93x | 3.29x | CN¥228.37 Million |
Industry Comparison
This section compares Qingdao Baheal Medical INC.'s net assets metrics with peer companies in the Medical Distribution industry.
Industry Context
- Industry: Medical Distribution
- Average net assets among peers: $9,529,984,903
- Average return on equity (ROE) among peers: 10.13%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Qingdao Baheal Medical INC. (301015) | CN¥2.90 Billion | 24.01% | 1.96x | $1.81 Billion |
| China National Accord Medicines Corp Ltd (000028) | $357.13 Million | 11.35% | 0.25x | $1.41 Billion |
| Shenzhen Glory Medical Co Ltd (002551) | $1.46 Billion | 7.01% | 0.62x | $394.67 Million |
| Shandong Realcan Pharmaceutical Co Ltd (002589) | $1.83 Billion | 9.92% | 2.11x | $647.35 Million |
| China National Accord Medicines Corp Ltd (200028) | $4.85 Billion | 13.45% | 1.64x | $120.33 Million |
| China Meheco Co Ltd (600056) | $1.54 Billion | 15.23% | 0.77x | $1.94 Billion |
| Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (600332) | $41.12 Billion | 7.25% | 1.05x | $4.03 Billion |
| China National Medicines Corp Ltd (600511) | $10.61 Billion | 13.23% | 1.03x | $2.90 Billion |
| Liaoning Cheng Da Co Ltd (600739) | $20.00 Billion | 4.74% | 0.66x | $2.30 Billion |
| Jointown Pharmaceutical Group Co Ltd (600998) | $4.00 Billion | 8.99% | 1.03x | $3.70 Billion |
About Qingdao Baheal Medical INC.
Qingdao Baheal Medical INC. engages in the research and development, production, wholesale, and retail of pharmaceutical products in China, the United States, Hong Kong, and the United Kingdom. The company offers bone health drugs under the D-Cal brand name; digestive drugs under the Mite brand name; liver disease drugs under the Fuzhenghuayu brand name; and urological drugs under the Betanli, Ha… Read more